Dehydrocostus lactone significantly ameliorated DSS-induced colitis in mice at doses of 5–15 mg/kg by covalently targeting both IKKα/β and Keap1, thereby suppressing NF-κB signaling and activating the Nrf2 pathway. This evidence concerns the gene KEAP1 and colitis.